Clinical trials: Zoledronic acid
Postmenopausal Osteoporosis
Pravastatin Reduces Acute Phase Response of Zoledronic Acid
Acute phase response (APR) is one of the most common adverse events in osteoporosis with zoledronic acid treatment. It's reported that this reaction is related to the blockade of the mevalonate pathway, leading to isopentenyl…
- Trial name
- NCT04719481
- Testing
- Pravastatin Sodium 80 MG
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
NEUROBLASTOMA
Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement
The purposes of this study are: 1. To find the highest dose of monthly intravenous Zometa that can be given with daily low doses of cyclophosphamide by mouth to children with recurrent or refractory neuroblastoma without causing…
- Trial name
- NCT00206388
- Testing
- Zolendric acid, Cyclophosphamide
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Baylor College of Medicine
Solid Tumor, Osteosarcoma
Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
This is a prospective open-labeled phase I trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and…
- Trial name
- METZOLIMOS (NCT02517918)
- Testing
- Sirolimus combined with CP, MT and ZA
- Where
- 3 sites in France
- Volunteers
- 23 people
- Sponsor
- Institut Bergonié
Osteoporosis, Osteonecrosis
Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
This study explores the effect of zoledronic acid on incident vertebral fractures and osteonecrotic lesions in children recently diagnosed with acute lymphoblastic leukemia.
- Conditions
- Osteoporosis, Osteonecrosis, Acute Lymphoblastic Leukemia
- Trial name
- NCT02632903
- Testing
- Zoledronic acid
- Where
- Canada
- Sponsor
- Children's Hospital of Eastern Ontario
Osteogenesis Imperfecta
Bisphosphonate Treatment of Osteogenesis Imperfecta
The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.
- Trial name
- NCT00063479
- Testing
- Zoledronic Acid
- Where
- 10 sites in United States
- Volunteers
- 158 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer
Select patients of primary breast cancer whose hormone receptor is positive and accepted postoperative adjuvant aromatase inhibitors for endocrine treatment.Treat them with zoledronic acid 4mg intravenous infusion every six…
- Trial name
- esozao (NCT01654367)
- Testing
- Zoledronic Acid and Aromatase Inhibitors
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University
Osteoporosis, Knee Osteoarthristis
The Effect of Long-term Use of Bisphosphonates on Femur Morphology
Recent studies have shown that bone modeling can occur throughout life, suggesting bone has a persistent ability of adapting structure to loading.
- Trial name
- NCT06621069
- Testing
- Bisphosphonates, Control
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Osteoporosis
Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer
The aim of this study is to determine if 3 monthly infusions of zoledronic acid, given over one year, improves the bone mineral density in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer
- Trial name
- NCT00520052
- Testing
- zoledronic acid
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- Wirral University Teaching Hospital NHS Trust
Progeria
Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
Hutchinson-Gilford Progeria Syndrome (Progeria) is a rare autosomal disease that results in premature death at a median age of 13 years due to cardiovascular and cerebralvascular compromise.
- Trial name
- NCT00916747
- Testing
- Lonafarnib, Zoledronic Acid, and Pravastatin
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Boston Children's Hospital
Lung Metastases, Tumor Necrosis
Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been widely used in the treatment of metastatic bone tumors.
- Trial name
- NCT03932071
- Testing
- Zoledronic Acid
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Osteoporosis, Liver Transplantation
The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients
Following liver transplantation, rapid bone loss occurs, particularly within the first 6 months post-transplant. This may be associated with fractures, most notable vertebral.
- Conditions
- Osteoporosis, Liver Transplantation, Fractures
- Trial name
- NCT00114556
- Testing
- zoledronic acid
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- Royal Prince Alfred Hospital, Sydney, Australia
Multiple Disability, Osteoporosis
Efficacy of Zoledronic Acid in Osteoporosis of Children With Multiple Disabilities
The main purpose of this study is the evaluation of the efficacy of zoledronic acid on bone density in children with osteoporosis caused by multiple disabilities. Secondary purposes are: 1.
- Trial name
- ZOMETA (NCT03301285)
- Testing
- Zoledronic Acid
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Central Hospital, Nancy, France
Osteoporosis
Zometa Study in Pediatric Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. It accounts for one fourth of all childhood cancers \& 74 % of childhood leukemia.
- Trial name
- NCT01656512
- Testing
- zolendronic acid, calcium & vitamin D
- Where
- Egypt
- Volunteers
- 95 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Osteoporosis, Osteoporosis, Postmenopausal
Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
This two-year observational, open-label clinical trial will evaluate the efficacy of a once-yearly infusion of zoledronic acid after denosumab discontinuation to maintain tissue mineral density and bone microarchitecture using…
- Conditions
- Osteoporosis, Osteoporosis, Postmenopausal, Osteopenia, Bone Loss
- Trial name
- NCT05405894
- Testing
- Zoledronic acid
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Osteogenesis Imperfecta
An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta
The investigators have currently finished conducting an international multi-center trial that compares the efficacy and safety of pamidronate and zoledronate in the treatment of moderate to severe forms of Osteogenesis Imperfecta…
- Trial name
- INFOI (NCT00982124)
- Testing
- Zoledronic Acid
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Shriners Hospitals for Children
FHA (Functional Hypothalamic Amenorrhea)
Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea
The goal of this study is to determine whether romosozumab will improve bone density in girls and women with functional hypothalamic amenorrhea (cessation of the menstrual period due to intense exercise, stress, or an eating…
- Trial name
- NCT06533865
- Testing
- Romosozumab, Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 114 people
- Sponsor
- Massachusetts General Hospital
Paget Disease
Zoledronate In the Prevention of Paget's Disease: Long Term Extension
Paget's disease of the bone (PDB) is a metabolic bone disorder which in some individuals can cause pain, bone deformity, arthritis and deafness, although in many patients it does not cause symptoms.
- Trial name
- ZiPP-LTE (NCT03859895)
- Where
- 21 sites in Australia, Belgium and 5 more
- Volunteers
- 287 people
- Sponsor
- University of Edinburgh
Osteoporosis
Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women
The purpose of this study is to evaluate the adequacy of zoledronic acid in maintaining bone mass after two years of treatment with Forteo, in postmenopausal women.
- Trial name
- NCT00361595
- Testing
- zoledronic acid
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- The Cleveland Clinic
Sarcoma
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00742924
- Testing
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- 88 sites in United States, Australia and 2 more
- Volunteers
- 24 people
- Sponsor
- Children's Oncology Group
Hematopoietic Stem Cell Transplantation
Zoledronate to Prevent Bone Health Complications in Pediatric Hematopoietic Stem Cell Transplant Survivors
The purpose of this pilot study is to investigate the safety and preliminarily assess efficacy of early intervention with zoledronate in high risk pediatric hematopoietic stem cell transplantation (HSCT) patients to prevent the…
- Trial name
- NCT07375290
- Testing
- Zoledronate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati